Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12281971 | 0.85 | TP53 (0.52) | TAAR1TSHRMAPK1 | |
| SCHEMBL322457 | 0.85 | KDM4E (0.50) | TAAR1TRIM24FAAHNR1H4MAPT | |
| SCHEMBL23224080 | 0.85 | TAAR1 (0.45) | TAAR1LMNAMAOB | |
| SCHEMBL2967940 | 0.84 | TRIM24 (0.55) | TRIM24NR1H4MAPTSIRT2TSHR | |
| SCHEMBL8050864 | 0.84 | TRIM24 (0.47) | TAAR1TRIM24FAAHNR1H4MAPT | |
| SCHEMBL20825574 | 0.84 | MAOB (0.49) | TAAR1TRIM24FAAHNR1H4MAPT | |
| SCHEMBL31538932 | 0.84 | MAOB (0.49) | TAAR1TRIM24FAAHNR1H4MAPT | |
| SCHEMBL6419825 | 0.84 | FAAH (0.49) | TAAR1TRIM24FAAHNR1H4MAPT | |
| SCHEMBL272030 | 0.84 | TRIM24 (0.43) | TAAR1TRIM24FAAHNR1H4MAPT | |
| SCHEMBL8050867 | 0.84 | TSHR (0.49) | TAAR1TRIM24FAAHNR1H4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2017-10-26 | — | — | US | disclosed |
| US-20170305894-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2017-10-26 | — | — | US | disclosed |
| US-20170305894-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2017-10-26 | — | — | US | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9591935-B2 | Therapeutic substituted cyclopentanes | ALLERGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-7468360-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2008121506-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008100809-A1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051374-A1 | Therapeutic Amides and related Compounds | ALLERGAN, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051374-A1 | Therapeutic Amides and related Compounds | GOT2, ACER2, GOT1 | TAAR1 3249/4885TRIM24 4721/4885FAAH 48/4885 |
| US-20080119539-A1 | THERAPEUTIC AMIDES | GOT2, GOT1, ARG2 | TAAR1 3010/4885TRIM24 4786/4885FAAH 81/4885 |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | TAAR1 4882/4885TRIM24 4645/4885FAAH 2895/4885 |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | TAAR1 3246/4885TRIM24 3682/4885FAAH 3626/4885 |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | TAAR1 1282/4885TRIM24 3947/4885FAAH 801/4885 |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | TAAR1 1663/4885TRIM24 1840/4885FAAH 1101/4885 |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | CYP11B2, CYP11B1, HMGCR | TAAR1 416/4885TRIM24 4492/4885FAAH 360/4885 |
| US-20170305894-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARA, PPARD | TAAR1 1072/4885TRIM24 2484/4885FAAH 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.